Ryan Cassaday

🧬 MRD in ALL: How to Use MRD Testing in Patients Who are Post-CAR-T or Post-HSCT? In Part 4 of this panel, Drs. @RyanCassaday (Fred Hutch), @NicholasShortMD (MD Anderson), and @LoriMuffly (Stanford) discuss MRD testing approaches and clinical implications. 📷 Watch on #Vumedi: tinyurl.com/3hkrsy8c #ALLsm

🧬 MRD in ALL: How often and for how long should you monitor? In Part 3 of this expert panel, Drs. @RyanCassaday (Fred Hutch), @NicholasShortMD (MD Anderson), and @LoriMuffly (Stanford) discuss key challenges in determining optimal MRD monitoring strategies in clinical practice. 🎥 Watch on VuMedi: tinyurl.com/3k5bmd3p #ALLsm #HemOnc

🧬 MRD in ALL: Which test should you use? In Part 2 of this panel, Drs. @RyanCassaday (Fred Hutch), @NicholasShortMD (MD Anderson), and @LoriMuffly (Stanford) discuss MRD testing approaches and clinical implications. 🔗 Watch on #Vumedi: tinyurl.com/4am68pc4 #ALLsm

⚖️ Should MRD status alter treatment in ALL? Drs. @RyanCassaday (Fred Hutch), @NicholasShortMD (MD Anderson), and @LoriMuffly (Stanford) explore real-world challenges of MRD-guided strategies in Part 1 of this expert panel. 🔗 Watch on #Vumedi: tinyurl.com/bddd4d32 #ALLsm #HemOnc #MedEd

Although brexu-cel is highly effective in relapsed or refractory B-ALL, its toxicities in routine practice appear more variable than those captured in the controlled trial setting. Read more, with exclusive insight from @RyanCassaday, of @fredhutch. ➡️ buff.ly/V3tV9xW

We want to hear from you! If you haven't already done so, please complete the survey below 👇#AcuteLymphoblasticLeukemia #BloodCancer #leukemia #Cancer loom.ly/oowOAfM Thank you!

🧬 #ASH25: Dr. @RyanCassaday of Fred Hutch reviews where frontline immunotherapy stands for B-cell ALL—and what limitations still exist. 🎥 Full talk: tinyurl.com/n24auty4 ➤ More from ASH: tinyurl.com/5c3k7ydn #ALLsm #HemOnc #MedEd #VuMedi

🩸 ALL updates from #ASH25: Dr. @RyanCassaday of Fred Hutch breaks down chemo-free strategies, relapse management, and MRD-based risk stratification in adults. Watch on #VuMedi: tinyurl.com/8xfbt3ek Access ASH 2025 Hub ➤ tinyurl.com/5c3k7ydn #ASH25 #ALLsm #HemOnc #MedEd

Enjoyed contributing to this thorough overview of asparaginase in treating #AYA in #ALL with my colleague Dr. DeAngelo. Great patient perspectives, too! #CME Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL reachmd.com/programs/cme/a… via @ReachMD

@bshah @mshadman @fredhutch @UWMedicine Means a lot from you!

@RyanCassaday @mshadman @fredhutch @UWMedicine This is a very nice summary of many of the challenges we all face treating ALL - kudos for putting this together!

Wrote this article inspired by observations treating adults with #ALL @fredhutch & @UWMedicine. As one of the most complex cancers for medical oncologists, I hope this helps clinicians, researchers, and pharma address the challenges it poses. #leusm authors.elsevier.com/sd/article/S24…

Great work by Dr Mitin Nachu, excellent R2 from @uwimrp who helped update our experience with DA-EPOCH for adults with ALL! Long term survival comparable to more complex regimens. Studies are ongoing @fredhutch and @UWMedicine using this with new agents. #ASH25 #leusm

Very proud of ⭐️ @CatherineTKLe for leading our multicenter analysis of incidence and factors associated with post-HCT CNS relapse in adults with ALL! She received an #ASH25 Abstract Achievement Award for her work! @LoriMuffly @RyanCassaday @fredhutch @StanfordMedRes

Starting soon at #ASH25! Editorial Advisory Board member @RyanCassaday joins the Education Program panel “Frontline Incorporation of Immune Targeting Agents in B-ALL - Triumphs and Challenges” See his work on CNS relapse risk in adult ALL: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert

Grateful for the opportunity to talk about this very important topic! #HemeSummit25

One month left to register for the 16th Annual Comprehensive Hematology & Oncology Review Course! Catch the Fred Hutch and UW faculty live at #MJ2601 in Seattle! 🔗 uw.cloud-cme.com/MJ2601 @RyanCassaday @MollyTokaz @UWMedicine @fredhutch @fac_uw

Join @NitinJainMD of @MDAndersonNews, and Dr. Navneet Majhail of @SarahCannonDocs at the 2025 National Summit on Hematologic Cancers #HemeSummit25 on Sep 19-20! Register TODAY: buff.ly/ppNGVHI #HemOnc #MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL

Join us Oct 6–10 in Seattle for the Hem & Onc Review Course. Featuring experts from Fred Hutch: ~Vyshak Venur – CNS Cancers ~Rosa Nadal Rios – Bladder Cancer ~Naveed Ali – HCT Network, learn, and grow! 🔗 uw.cloud-cme.com/MJ2601 @RyanCassaday @MollyTokaz @UWMedicine @fredhutch

@drjgauthier @TalhaBadarMD @AABB Here is link to said guidelines: jamanetwork.com/journals/jama/…

@drjgauthier @TalhaBadarMD Thanks, @drjgauthier and nice work @TalhaBadarMD. @AABB just published new guidelines suggesting platelet transfusion before LP only when < 20k/uL. I’m generally comfortable doing an LP if >30k/uL. Clearly the procedurist’s comfort and the circumstances need to be considered!

My editorial 🩸 Safe Platelet Count for Lumbar Puncture in Hematologic Malignancies While 50 ×10⁹/L has long been considered the “safe” threshold for lumbar puncture, recent studies suggest lower counts (40 ×10⁹/L) may be acceptable in select patients with hem malignancies The risk of spinal hematoma is very low, but delays in diagnostic or therapeutic LP due to transfusion can adversely impact outcomes. Takeaway: Evidence supports a more flexible, individualized approach rather than a rigid platelet cutoff. Prospective trials are needed to establish definitive guidelines. #leusm #AML #ALL #MedTwitter @Haematologica doi.org/10.3324/haemat…